Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Spotlight: Saluda Hopes To 'Evoke' From Down Under With First Closed-Loop Spine-Stim System

Executive Summary

Aiming to improve the lives of patients living with chronic, intractable pain, Australian start-up Saluda Medical Pty Limited is the first and only neuromodulation company in the world to develop a closed-loop spinal cord stimulation system (SCS). Unlike other SCS systems marketed today, Saluda’s device, currently in clinical trials, is designed to measure the spinal cord’s response to electrical stimulation, and then respond to patient's preferred stimulation. 

You may also be interested in...



Medtronic And Boston Scientific Finance Saluda's Neuromodulation System

Saluda Medical has secured funds from Medtronic and Boston Scientific to support the development of its spinal cord stimulation system for pain management.

Canadian Firm Aims To Cast Wide Net To Grow Using Marine Algae Phytoplankton In Nutrition

Marine algae phytoplankton is abundant with numerous vitamins and minerals and is found on the ocean’s surface. Blugenics Innovations markets Karen brand powder and tablet line with proprietary phytoplankton ingredient it also provides to other firms.

Study Finds Data Scarce Where US FDA Wants To Gauge Hemp Safety – Reproductive Toxicity

First systematic mapping study of safety concerns for consumer use of cannabidiol identifies knowledge gaps for reproductive and developmental toxicity. No traditional, guideline-compliant developmental and reproductive toxicity study was available in the public domain through December 2020.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT122210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel